Accelerate

• President Trump signed an executive order directing federal regulators to fast-track FDA review of psychedelic drugs including psilocybin and ibogaine for treating depression, anxiety, and PTSD. • The order allocates $50 million in federal funds to states implementing or developing psychedelic treatment programs as part of a federal-state partnership initiative. • Trump highlighted that over 14 million American adults have serious mental illness, with approximately 8 million on prescription medication, framing psychedelics as addressing a national mental health crisis including suicide prevention.

• President issues executive order on April 18, 2026, to speed medical treatments for serious mental illness using psychedelic drugs including ibogaine compounds. • Order highlights clinical studies showing potential for patients with persistent conditions unresponsive to standard therapies. • Directs federal agencies to prioritize research, approvals, and access to innovative mental health interventions nationwide.

President signed executive order directing FDA to expedite review of psychedelic drugs including ibogaineDonald Trump on Saturday announced reforms intended to speed up access to medical research and treatment based on psychedelic drugs.The president signed an executive order directing the federal Food and Drug Administration (FDA) to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder. Continue reading...

• Centers for Medicare and Medicaid Services published a proposed rule on Friday requiring health insurance companies and states to resolve non-urgent prior authorization requests for prescription drugs within 24 hours. • The regulation mandates Medicaid and CHIP insurers, plus state administrators, to publicly disclose denial rates and respond faster to improve patient access. • This addresses delays in medication approvals, potentially benefiting millions enrolled in these programs amid ongoing affordability challenges.

• Amazon posted stronger-than-expected Q1 2026 earnings Wednesday, with net income reaching $8.3 billion and revenue climbing 18% year-over-year to $147 billion, driven by robust AWS cloud services demand. • AWS revenue grew 22% annually to $28.4 billion, outpacing analyst expectations and demonstrating the resilience of enterprise cloud spending despite macroeconomic uncertainties. • Management raised full-year 2026 revenue guidance to $625 billion, representing 14% growth, citing continued momentum in cloud computing and advertising as key tailwinds for sustained profitability.

• Bank mergers are surging in the US, driving increased branch closures particularly in rural areas as institutions cut costs to compete with online banks. • Ohio leads with six closures announced in 2026, including Cincinnati, Cleveland, and Columbus; Texas follows with four, while South Dakota, Delaware, Illinois, and Florida each report three. • Closures echo a decade-long trend, with 15% of US bank branches shuttered between 2015 and 2024 per Statista data.

• Eli Lilly announced a collaboration with Nvidia to establish a co-innovation AI lab combining computing power with scientific expertise for faster drug discovery. • The partnership targets AI applications in identifying drug candidates, optimizing clinical trials, and reducing failure rates in biotech development. • This non-tech firm's AI push exemplifies how pharma giants are leveraging partnerships to lead in AI-driven innovation beyond traditional tech sectors.